Overview

A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

Status:
TERMINATED

Trial end date:
2025-08-15

Target enrollment:

Participant gender:

Summary

A randomised, multi-centre, intra-patient imaging and dosimetry crossover study of lutetium (177Lu) rhPSMA 10.1 and lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in patients with non-curative metastatic prostate cancer

Phase:

EARLY_PHASE1

Details

Lead Sponsor:

Blue Earth Therapeutics Ltd

Collaborator:

Medpace, Inc.

Treatments:

Lutetium
Lutetium-177
Pluvicto